PACIRA BIOSCIENCES, INC. Accrued Liabilities, Current
PACIRA BIOSCIENCES, INC. (PCRX) had Accrued Liabilities, Current of $93.50 million as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current › Accrued Liabilities, Current
us-gaap:AccruedLiabilitiesCurrent · last filed 2026-08-04
- 2026-06-30: Accrued Liabilities, Current $93.50M.
- 2026-03-31: Accrued Liabilities, Current $84.96M.
- 2025-12-31: Accrued Liabilities, Current $95.60M.
- 2025-09-30: Accrued Liabilities, Current $79.64M.
| Period end | Accrued Liabilities, Current | Accrued Liabilities, Current as first filed |
|---|---|---|
| 2026-06-30 | $93.50M 10-Q · filed 2026-08-04 | |
| 2026-03-31 | $84.96M 10-Q · filed 2026-04-30 | |
| 2025-12-31 | $95.60M 10-Q · filed 2026-08-04 | |
| 2025-09-30 | $79.64M 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $71.02M 10-Q · filed 2025-08-05 | |
| 2025-03-31 | $80.07M 10-Q · filed 2025-05-08 | |
| 2024-12-31 | $80.12M 10-K · filed 2026-02-26 | |
| 2024-09-30 | $76.38M 10-Q · filed 2024-11-06 | |
| 2024-06-30 | $64.81M 10-Q · filed 2024-07-30 | |
| 2024-03-31 | $66.82M 10-Q · filed 2024-05-07 | |
| 2023-12-31 | $64.24M 10-K · filed 2025-02-27 | |
| 2023-09-30 | $59.88M 10-Q · filed 2023-11-02 | |
| 2023-06-30 | $56.22M 10-Q · filed 2023-08-02 | |
| 2023-03-31 | $61.63M 10-Q · filed 2023-05-03 | |
| 2022-12-31 | $89.78M 10-K · filed 2024-02-29 | |
| 2022-09-30 | $76.36M 10-Q · filed 2022-11-03 | |
| 2022-06-30 | $77.28M 10-Q · filed 2022-08-03 | |
| 2022-03-31 | $87.67M 10-Q · filed 2022-05-04 | |
| 2021-12-31 | $127.56M 10-K · filed 2023-02-28 | |
| 2021-09-30 | $50.80M 10-Q · filed 2021-11-03 | |
| 2021-06-30 | $52.16M 10-Q · filed 2021-08-03 | |
| 2021-03-31 | $50.24M 10-Q · filed 2021-05-04 | |
| 2020-12-31 | $70.97M 10-K · filed 2022-02-28 | |
| 2020-09-30 | $60.40M 10-Q · filed 2020-10-30 | |
| 2020-06-30 | $47.68M 10-Q · filed 2020-08-06 | |
| 2020-03-31 | $44.72M 10-Q · filed 2020-05-07 | |
| 2019-12-31 | $70.43M 10-K · filed 2021-03-01 | |
| 2019-09-30 | $61.00M 10-Q · filed 2019-11-08 | |
| 2019-06-30 | $51.91M 10-Q · filed 2019-08-08 | |
| 2019-03-31 | $39.70M 10-Q · filed 2019-05-02 | |
| 2018-12-31 | $45.87M 10-K · filed 2020-02-21 | |
| 2018-09-30 | $40.36M 10-Q · filed 2018-11-01 | |
| 2018-06-30 | $38.43M 10-Q · filed 2018-08-02 | |
| 2018-03-31 | $33.02M 10-Q · filed 2018-05-03 | |
| 2017-12-31 | $41.06M 10-K · filed 2019-02-28 | |
| 2017-09-30 | $39.70M 10-Q · filed 2017-11-08 | |
| 2017-06-30 | $46.76M 10-Q · filed 2017-08-02 | |
| 2017-03-31 | $34.90M 10-Q · filed 2017-05-04 | |
| 2016-12-31 | $36.67M 10-K · filed 2018-02-28 | |
| 2016-09-30 | $31.08M 10-Q · filed 2016-11-02 | |
| 2016-06-30 | $38.33M 10-Q · filed 2016-08-04 | |
| 2016-03-31 | $29.07M 10-Q · filed 2016-05-02 | |
| 2015-12-31 | $35.38M 10-K · filed 2017-03-01 | |
| 2015-09-30 | $30.30M 10-Q · filed 2015-10-27 | |
| 2015-06-30 | $26.79M 10-Q · filed 2015-07-30 | |
| 2015-03-31 | $25.30M 10-Q · filed 2015-04-30 | |
| 2014-12-31 | $28.31M 10-K · filed 2016-02-25 | $28.45M 10-K · filed 2015-02-24 |
| 2014-09-30 | $23.38M 10-Q · filed 2014-10-30 | |
| 2014-06-30 | $23.04M 10-Q · filed 2014-07-31 | |
| 2014-03-31 | $16.91M 10-Q · filed 2014-05-01 | |
| 2013-12-31 | $17.89M 10-K · filed 2015-02-24 | |
| 2013-09-30 | $15.57M 10-Q · filed 2013-10-31 | |
| 2013-06-30 | $12.26M 10-Q · filed 2013-08-06 | |
| 2013-03-31 | $9.87M 10-Q · filed 2013-05-08 | |
| 2012-12-31 | $9.79M 10-K · filed 2014-02-25 | |
| 2012-09-30 | $13.04M 10-Q · filed 2012-11-01 | |
| 2012-06-30 | $9.28M 10-Q · filed 2012-08-09 | |
| 2012-03-31 | $7.04M 10-Q · filed 2012-05-09 | |
| 2011-12-31 | $7.16M 10-K · filed 2013-03-07 | |
| 2011-09-30 | $5.00M 10-Q · filed 2011-10-31 | |
| 2011-06-30 | $3.64M 10-Q · filed 2011-08-11 | |
| 2010-12-31 | $4.98M 10-K · filed 2012-03-27 | $3.52M 10-Q · filed 2011-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |